Dry eye disease (DED) is widely believed that immune-related inflammation plays an important role in its pathogenesis. Tacrolimus (FK506) has a certain therapeutic effect on ocular inflammation in dry eye by inhibiting calcineurin or MAPK pathway in T lymphocytes, NF-κB pathway in ocular surface cells, and apoptosis of ocular surface cells. Currently, studies on the topical use of tacrolimus in the treatment of dry eye have focused on dry eye with systemic immune diseases, including chronic graft-versus-host disease, Sjgren's syndrome, cicatoid pemphigoid, Steven-Johnson syndrome, etc.(Int Rev Ophthalmol, 2022, 46: 318-323)